This Article Full Text (PDF) All Versions of this Article: 1352458508096875v1 15/2/229    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fagius, J Articles by Öberg, G Search for Related Content PubMed PubMed Citation Articles by Fagius, J Articles by Öberg, G Social Bookmarking                         What's this?

Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation

Department of Neurology, University Hospital, Uppsala, Sweden jan.fagius{at}akademiska.se

J Lundgren

Department of Paediatrics, Lund University Hospital, Lund, Sweden

G Öberg

Department of Haematology, University Hospital, Uppsala, Sweden

Background

During the last 15 years, high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) has globally been performed for severe multiple sclerosis (MS). Most patients have been in progressive phase with long disease duration. As a rule, treatment effect has been minor or moderate.

Patients

Since 2004, we have performed HSCT in nine young patients with "malignant" relapsing–remitting MS. Criteria for treatment were short duration of disease; very frequent, severe relapses; recent improvement periods indicating potential for recovery after strong immunosuppression.

Findings

Median age at treatment was 27 (range 9–34) years, MS duration 26 (4–100) months, and annualized relapse rate 10 (4–12). Median Disability Status Scale (extended disability status scale, EDSS) at HSCT was 7.0 (3.5–8.0). Median follow-up time April 2008 is 29 (23–47) months. Median EDSS improvement is 3.5 (1.0–7.0), clearly surpassing most previous reports. One patient relapsed mildly with rapid recovery 7 months after HSCT. All patients are otherwise stable, median EDSS being 2.0 (0–6.0). Before HSCT, 61 relapses occurred in 82 patient months; during follow-up, one relapse in 289 patient months.

Conclusion

This small series of patients with "malignant" relapsing–remitting MS suggests HSCT to be an effective treatment option for this relatively rare disease course. It further suggests that future criteria for HSCT in MS should be close to the present ones.

Key Words: early MS • high-dose chemotherapy • HSCT • hematopoietic stem cell transplantation • malignant MS • relapsing–remitting MS

This version was published on February 1, 2009

Multiple Sclerosis, Vol. 15, No. 2, 229-237 (2009)
DOI: 10.1177/1352458508096875


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?